Clinical Trial Update: GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating GVAX Pancreas Vaccine with cyclophosphamide in combination with nivolumab and SBRT for borderline resectable pancreatic cancer has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Cancer
• Pancreatic Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• GVAX Pancreas Vaccine
• nivolumab (nivolumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-02-03